Protracted 'pro-addictive' phenotype produced in mice by pre-adolescent phenylpropanolamine

Neuropsychopharmacology

Volumn 32, Issue 8, 2007, Pages 1760-1773

  Szumlinski, Karen K ^a   Liu, Andrew ^a   Penzner, Jeffery H ^a   Lominac, Kevin D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cocaine; Nucleus accumbens; Phenylpropanolamine; Pre adolescence; Reward; Sensitization

Indexed keywords

4 AMINOBUTYRIC ACID; CATECHOLAMINE; COCAINE; GLUTAMIC ACID; NON PRESCRIPTION DRUG; NORADRENALIN; PHENYLPROPANOLAMINE; SEROTONIN;

AMINO ACID BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; C57BL 6 MOUSE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERANCE; FEMALE; LOCOMOTION; MALE; MICRODIALYSIS; MOUSE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; SENSITIZATION; STEREOTYPY;

AMINO ACIDS; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; COCAINE; COCAINE-RELATED DISORDERS; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PHENOTYPE; PHENYLPROPANOLAMINE; SEX FACTORS; STEREOTYPED BEHAVIOR; SYMPATHOMIMETICS;

EID: 34447499176     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301306     Document Type: Article

References (99)

1. Adriani W, Granstrem O, Macri S, Izykenova G, Dambinova S, Laviola G (2004). Behavioral and neurochemical vulnerability during adolescence in mice: studies with nicotine. Neuropsychopharmacology 29: 869-878.
2. Andersen SL, Arvanitogiannis A, Pliakas AM, LeBlanc C, Carlezon Jr WA (2002). Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 5: 13-14.
3. Augustyniak PN, Kourrich S, Rezazadeh SM, Stewart J, Arvanitogiannis A (2006). Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder. Behav Brain Res 167: 379-382.
4. Badiani A, Oates MM, Robinson TE (2000). Modulation of morphine sensitization in the rat by contextual stimuli. Psychopharmacology 151: 273-282.
5. Badiani A, Robinson TE (2004). Drug-induced neurobehavioral plasticity: the role of environmental context. Behav Pharmacol 15: 327-339.
6. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S et al (2003). Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 6: 743-749.
7. Baldessarini RJ, Harris JE (1974). Effects of amphetamines on the metabolism of catecholamines in the rat brain. J Psychiatr Res 11: 41-43.
8. Bardo MT, Bevins BA (2000). Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153: 31-43.
9. Belzung C, Misslin R, Vogel E, Dodd RH, Chapouthier G (1987). Anxiogenic effects of methyl-β-carboline-carboxylate in a light/ dark choice situation. Pharmacol Biochem Behav 28: 29-33.
10. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV (1999). Pharmacotherapy of attention deficit/hyperactivity disorder reduces risk for substance abuse disorder. Pediatrics 104: e20, 1-5.
11. Bolanos CA, Glatt SJ, Jackson D (1998). Subsensitivity to dopaminergic drugs in periadolescent rats: a behavioral and neurochemical analysis. Brain Res Dev Brain Res 111: 25-33.
12. Brebner K, Childress AR, Roberts DC (2002). A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 37: 478-484.
13. Brog JS, Salyapongse A, Deutch AY, Zahm DS (1993). The patterns of afferent innervation of the core and shell in the 'accumbens' part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold. J Comp Neurol 338: 255-278.
14. Browman KE, Badiani A, Robinson TE (1998). The influence of environment on the induction of sensitization to the psychomotor activating effects of intravenous cocaine in rats is dose-dependent. Psychopharmacology 137: 90-98.
15. Carlezon Jr WA, Konradi C (2004). Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 47(Suppl 1): 47-60.
16. Carlezon Jr WA, Mague SC, Andersen SL (2003). Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiat 54: 1330-1337.
17. Chait LD, Uhlenhuth EH, Johanson CE (1988). Phenylpropanolamine: reinforcing and subjective effects in normal human volunteers. Psychopharmacology 96: 212-217.
18. Cirulli F, Laviola G (2000). Paradoxical effects of D-amphetamine in infant and adolescent mice: role of gender and environmental risk factors. Neurosci Biobehav Rev 24: 73-84.
19. Cohen S (1972). Cocaine. J Amer Med Assoc 231: 74-75.
20. Covington III HE, Miczek KA (2003). Vocalizations during withdrawal from opiates and cocaine: possible expressions of affective distress. Eur J Pharmacol 467: 1-13.
21. Dafny N, Yang PB (2006). The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull 68: 393-405.
22. Deroche-Gamonet V, Belin D, Piazza PV (2004). Evidence for addiction-like behavior in the rat. Science 305: 1014-1017.
23. Di Chiara G (1999). Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 375: 13-30.
24. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C et al (2004). Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47(Suppl 1): 227-241.
25. Eisenberg MS, Maher TJ, Silverman HI (1987). A comparison of the effects of phenylpropanolamine, d-amphetamine and d-norpseudoephedrine on open-field locomotion and food intake in the rat. Appetite 9: 31-37.
26. Ettenberg A, Geist TD (1991). Animal model for investigating the anxiogenic effects of self-administered cocaine. Psychopharmacology 103: 455-461.
27. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW (1999). Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann NY Acad Sci 877: 412-438.
28. Everitt BJ, Wolf ME (2002). Psychomotor stimulant addiction: a neural systems perspective. J Neurosci 22: 3312-3320.
29. Frantz KJ, O'Dell LE, Parsons LH (2006). Behavioral and neurochemical responses to cocaine in periadolescent and adult rats. Neuropsychopharmacology [E-pub ahead of print; doi:10.1038/sj.npp. 1301130].
30. Gardner EL, Schiffer WK, Horan BA, Highfield D, Dewey SL, Brodie JC et al (2002). Gamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats. Synapse 46: 240-250.
31. Gawin FH (1991). Cocaine addiction: psychology and neurophysiology. Science 251: 1580-1586.
32. Gawin FH, Kleber HD (1986). Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 43: 107-113.
33. Gillman MA, Lichtigfeld FJ, Harker N (2006). Psychotropic analgesic nitrous oxide for acute cocaine withdrawal in man. Int J Neurosci 116: 847-857.
34. Golembiowska K, Zylewska A (1999). Effect of antidepressant drugs on veratridine-evoked glutamate and aspartate release in rat prefrontal cortex. Pol J Pharmacol 51: 63-70.
35. Guerriero RM, Hayes MM, Dhaliwal SK, Ren JQ, Kosofsky BE (2006). Preadolescent methylphenidate versus cocaine treatment differ in the expression of cocaine-induced locomotor sensitization during adolescence and adulthood. Biol Psychiatry 60: 1171-1180.
36. Hall FS, Sora I, Drgonova J, Li XF, Goeb M, Uhl GR (2004). Molecular mechanisms underlying the rewarding effects of cocaine. Ann NY Acad Sci 1025: 47-56.
37. Hoffman BB (2001). Catecholamines, sympathomimetics, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Gilman AG (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill: New York. pp 215-268.
38. Ihalainen JA, Tanila H (2004). In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse nucleus accumbens. J Neurochem 91: 49-56.
39. Itzhak Y, Martin JL (2000). Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice. Psychopharmacology 151: 226-233.
40. Ito K, Abekawa T, Koyama T (2006). Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine. Psychopharmacology 187: 293-302.
41. Jung ME, Lal H, Gatch MB (2002). The discriminative stimulus effects of pentylenetetrazol as a model of anxiety: recent developments. Neurosci Biobehav Rev 26: 429-439.
42. Kalivas PW, Volkow N, Seamans J (2005). Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 45: 647-650.
43. Koe BK (1976). Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J Pharmacol Exp Ther 199: 649-661.
44. Kuczenski R, Segal DS, Aizenstein ML (1991). Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci 11: 2703-2712.
45. Lee F, Stafford I, Hoebel BG (1989). Similarities between the stimulus properties of phenylpropanolamine and amphetamine. Psychopharmacology 97: 410-412.
46. Lominac KD, Kapasova Z, Hannun RA, Patterson C, Middaugh LD, Szumlinski KK (2006). Behavioral and neurochemical interactions between Group 1 mgluR antagonists and ethanol: potential insight into their anti-addictive properties. Drug Alcohol Dep 85: 142-156.
47. Lominac KD, Oleson EB, Pava M, Klugmann M, Schwarz MK, Seeburg PH et al (2005). Distinct roles for different Homer1 isoforms in behaviors and associated prefrontal cortex function. J Neurosci 25: 11586-11594.
48. Mague SD, Andersen SL, Carlezon Jr WA (2005). Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry 57: 120-125.
49. Marek GJ, Aghajanian GK (1999). 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367: 197-206.
50. Mariathasan EA, Stolerman IP (1992). Drug discrimination studies in rats with caffeine and phenylpropanolamine administered separately and as mixtures. Psychopharmacology 109: 99-106.
51. Markou A, Koob GF (1991). Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 4: 17-26.
52. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM (2005). The nature, time course and severity of methamphetamine withdrawal. Addiction 100: 1320-1329.
53. McMahon LR, Wellman PJ (1996). Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus. Physiol Behav 59: 63-69.
54. Miller DK, Nation JR, Wellman PJ (1999). Sensitization of anorexia and locomotion induced by chronic administration of ephedrine in rats. Life Sci 65: 501-511.
55. Mittleman G, Rushing PA, Winders SE (1993). Effects of phenylpropanolamine on regulatory and nonregulatory ingestion in adult rats. Physiol Behav 54: 515-521.
56. Niculescu M, Ehrlich ME, Unterwald EM (2005). Age-specific behavioral responses to psychostimulants in mice. Pharmacol Biochem Behav 82: 280-288.
57. Olausson P, Engel JA, Soderpalm B (2000). Effects of serotonergic manipulations on the behavioral sensitization and disinhibition associated with repeated amphetamine treatment. Pharmacol Biochem Behav 66: 211-220.
58. Paine TA, Jackman SL, Olmstead MC (2002). Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol 13: 511-523.
59. Patrick KS, Kilts CD, Breese GR (1981). Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem 24: 1237-1240.
60. Pennartz CM, Groenewegen HJ, Lopes da Silva FH (1994). The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog Neurobiol 42: 719-761.
61. Pert A, Post R, Weiss SR (1990). Conditioning as a critical determinant of sensitization induced by psychomotor stimulants. NIDA Res Monogr 97: 208-241.
62. Pierce RC, Bell K, Duffy P, Kalivas PW (1996). Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J Neurosci 16: 1550-1560.
63. Post RM, Kopanda RT (1976). Cocaine, kindling, and psychosis. Am J Psychiatry 133: 627-634.
64. Raven MA, Necessary BD, Danluck DA, Ettenberg A (2000). Comparison of the reinforcing and anxiogenic effects of intravenous cocaine and cocaethylene. Exp Clin Psychopharmacol 8: 117-124.
65. Roberts DC (2005). Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol Behav 86: 18-20.
66. Robinson TE, Berridge KC (2001). Incentive-sensitization and addiction. Addiction 96: 103-114.
67. Robinson TE, Browman KE, Crombag HS, Badiani A (1998). Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev 22: 347-354.
68. Rushing PA, Winders SE, Mittleman G (1993). Effects of phenylpropanolamine infusion and withdrawal on body weight and dietary composition in male and female rats. Physiol Behav 54: 523-530.
69. Scheel-Kruger J, Cools AR, van Wel PM (1977). Muscimol a GABA-agonist injected into the nucleus accumbens increases apomorphine stereotypy and decreases the motility. Life Sci 21: 1697-1702.
70. Segal DS, Kuczenski R (1997). An escalating dose 'binge' model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci 17: 2551-2566.
71. Sherer MA (1988). Intravenous cocaine: psychiatric effects, biological mechanisms. Biol Psychiatry 24: 865-885.
72. Shimosato K, Ohkuma S (2000). Simultaneous monitoring of conditioned place preference and locomotor sensitization following repeated administration of cocaine and methamphetamine. Pharmacol Biochem Behav 66: 285-292.
73. Smith AJ, Bolam JP (1990). The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends Neurosci 13: 259-265.
74. Solanto MV (1998). Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 94: 127-152.
75. Spear LP, Brake SC (1983). Periadolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol 16: 83-109.
76. Spinella M (2003). Relationship between drug use and prefrontal- associated traits. Addict Biol 8: 67-74.
77. Steketee JD, Beyer CE (2005). Injections of baclofen into the ventral medial prefrontal cortex block the initiation, but not the expression, of cocaine sensitization in rats. Psychopharmacology 180: 352-358.
78. Szumlinski KK, Abernathy KE, Oleson EB, Klugmann M, Lominac KD, He D-Y et al (2006). Homer isoforms differentially regulate cocaine-induced neuroplasticity. Neuropsychopharmacology 31: 768-777.
79. Szumlinski KK, Allan M, Talangbayan H, Tracey A, Szechtman H (1997). Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacology 134: 193-200.
80. Szumlinski KK, Dehoff MH, Kang SH, Frys KA, Lominac KD, Rohrer J et al (2004a). Homer proteins regulate vulnerability to cocaine. Neuron 43: 401-413.
81. Szumlinski KK, Frys KA, Kalivas PW (2004b). Dissociable roles for the dorsal and median raphé in the facilitatory effect of 5-HT1A receptor stimulation upon cocaine-induced locomotion and sensitization. Neuropsychopharmacology 29: 1675-1687.
82. Szumlinski KK, Haskew RE, Balogun MY, Maisonneuve IM, Glick SD (2000a). Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: implications for their antiaddictive properties. Pharmacol Biochem Behav 69: 485-491.
83. Szumlinski KK, Lominac KD, Frys KA, Middaugh LD (2005a). Genetic variation in heroin-induced changes in behaviour: effects of B6 strain dose on conditioned reward and locomotor sensitization. Genes Brain Behav 4: 324-336.
84. Szumlinski KK, Lominac KD, Kleschen M, Oleson EB, Dehoff M et al (2005b). Behavioural and neurochemical phenotyping of Homer1 mutant mice: possible implications for schizophrenia. Genes Brain Behav 4: 273-288.
85. Szumlinski KK, Lominac KD, Oleson EB, Walker JK, Mason A, Dehoff MH et al (2005c). Homer2 is necessary for ethanol-induced neuroplasticity. J Neurosci 25: 7054-7061.
86. Szumlinski KK, Maisonneuve IM, Glick SD (2000b). Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine. Eur J Pharmacol 398: 259-262.
87. Szumlinski KK, McCafferty CA, Maisonneuve IM, Glick SD (2000c). Interactions between 18-methoxycoronaridine (18-MC) and cocaine: dissociation of behavioural and neurochemical sensitization. Brain Res 871: 245-258.
88. Szumlinski KK, Price KL, Frys KA, Middaugh LD (2002). Unconditioned and conditioned factors contribute to the 'reinstatement' of cocaine place conditioning following extinction in C57BL/6 mice. Behav Brain Res 136: 151-160.
89. Tang XC, McFarland K, Cagle S, Kalivas PW (2005). Cocaine-induced reinstatement requires endogenous stimulation of μ-opioid receptors in ventral pallidum. J Neurosci 25: 4512-4520.
90. Thiébot M-H, Kloczko J, Chermat R, Puech AJ, Soubri P, Simon P (1981). Enhancement of cocaine-induced hyperactivity in mice by benzodiazepines: evidence for an interaction of GABAergic processes with catecholaminergic neurons? Eur J Pharmacol 76: 335-343.
91. Torres-Reveron A, Dow-Edwards DL (2005). Repeated administration of methylphenidate in young, adolescent, and mature rats affects the response to cocaine later in adulthood. Psychopharmacology 181: 38-47.
92. Vanderschuren LJ, Beemster P, Schoffelmeer AN (2003). On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization. Psychopharmacology 169: 176-185.
93. Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 151: 99-120.
94. Wellman PJ (1990). The pharmacology of the anorexic effect of phenylpropanolamine. Drugs Exp Clin Res 16: 487-495.
95. Wellman PJ, Shelton K, Schenk S (1989). Self-administration of phenylpropanolamine (PPA) by rats previously trained to self-administer amphetamine. Pharmacol Biochem Behav 34: 187-191.
96. Woolverton WL, Johanson CE, de la Garza R, Ellis S, Seiden LS, Schuster CR (1986). Behavioral and neurochemical evaluation of phenylpropanolamine. J Pharmacol Exp Ther 237: 926-930.
97. Xi ZX, Ramamoorthy S, Shen H, Lake R, Samuvel DJ, Kalivas PW (2003). GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J Neurosci 23: 3498-3505.
98. Zhang XY, Kehoe P, Kosten TA (2006). Neonatal isolation alters estrous cycle effects on ventral striatal extracellular monoamine levels. Prog Neuropsychopharmacol Biol Psychiatry 30: 504-511.
99. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F (2000). Trends in the prescribing of psychotropic medication to preschoolers. J Amer Med Assoc 283: 1025-1030.